Across TCGA pan-cancer cohorts, CNTN4-AS2 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated CNTN4-AS2 data layer.
The strongest signal is observed in brain lower grade glioma (LGG), where higher CNTN4-AS2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated CNTN4-AS2 expression acts as an unfavorable survival marker, although some lineages such as LGG and CHOL show a favorable association.
LGG, STAD, and CHOL are the cancer types where CNTN4-AS2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.